# Safety and Pharmacokinetics Study of amlodipine10mg and candesartan32mg

> **NCT01806311** · PHASE1 · COMPLETED · sponsor: **HanAll BioPharma Co., Ltd.** · enrollment: 36 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Candesartan32mg
- **DRUG:** Amlodipine10mg

## Key facts

- **NCT ID:** NCT01806311
- **Lead sponsor:** HanAll BioPharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01806311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01806311, "Safety and Pharmacokinetics Study of amlodipine10mg and candesartan32mg". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01806311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*